However, coadministration of rosiglitazone or pioglitazone with insulin has been shown to increase the risk of AEs such as weight gain, edema, and left ventricular hypertrophy, which can lead to HF (Henriksen et al., 2011; Giri et al., 2016). Here, INS is linked to left ventricular hypertrophy.